NCT05636267View on ClinicalTrials.gov

Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

114

Participants

Timeline

Start Date

February 10, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

March 31, 2025

Conditions
NSCLC
Interventions
DRUG

AK119

AK119 IV every 3 weeks.

DRUG

AK112

AK112 IV every 3 weeks.

DRUG

Pemetrexed

Pemetrexed IV every 3 weeks.

DRUG

Carboplatin

Carboplatin IV every 3 weeks.

Trial Locations (1)

Unknown

RECRUITING

Guangdong Provincial People's Hospital, Guangzhou

Sponsors

Lead Sponsor

Akeso
All Listed Sponsors
lead

Akeso

INDUSTRY

NCT05636267 - Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients | Biotech Hunter | Biotech Hunter